biliary stricture

lumbar spinal stenosis | narrow lumbar canal | spinal stenosis | narrowing of the lumbar vertebral canal

spinal stenosis | spinal canal stenosis | narrowing of the vertebral canal | narrow spinal canal

bronchostenosis

Enterostenosis Obstructive ileus NOS Occlusion | Stenosis | Stricture | of colon or intestine

hypertrophic obstructive cardiomyopathy | HOCM | obstructive hypertrophic cardiomyopathy | idiopathic hypertrophic subaortic stenosis | hypertrophic obstructive myocardiopathy | asymmetrical septal hypertrophy | obstructive cardiomyopathy | obstructive myocardiopathy

Another very surprising finding, the stenosis of the veins, the usual cardinal criterion for CCSVI, if there is any abnormality at all, from the post-mortem studies that have appeared since or more sophisticated imaging techniques, the real culprit could be perhaps valvular problems in the neck veins and not at all a stenotic problem.

One of the points is that there is someone who questions the existence of stenosis or significant stenosis in veins.

...re with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with both primary progressive and secondary progressive forms of the disease be included, and if so, how will statistical significance be ensured; (i) given that research has shown numerous venous abnormalities in the head, neck, and chest of MS patients, (i) how will ...[+++] statistical significance be ensured if there are only a limited number of patients, but multiple types of venous or valvular abnormality, (ii) how will a venous stenosis be measured (e.g. diameter, size); (j) what outcomes will be measured, including, but not limited to, EDSS, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, and at what time scales; (k) will patient-reported quality of life scores be included, and if so, what is the specific methodology; (l) what specific follow-up care will patients undergoing the “sham” procedure and treatment receive, and at what specific time periods; (m) if patients received the “sham” procedure, within what time period will they receive treatment; (n) how will the results of this study be interpreted within the growing international body of research, (i) to how many studies will this study be compared, (ii) to how many studies will this study be directly comparable; (o) what long-term follow-up will those enrolled in the trial receive and for what time period; (p) what is the cost of the trial, and what are each of the partners contributing, including, but not limited to funding, equipment, expertise, pharmaceutical products; (q) what is the cost of each diagnosis, (i) what is the cost of each “sham” procedure, (ii) what is the cost of each procedure; and (r) who is overseeing the trial, (i) the safety of the patients, (ii) the integrity of the results? ...

evidence of hydrocephalus, in particular enlargement of the ventricles, stenosis of the cerebral aqueduct and thinning of the cerebral hemispheres.